🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesNNT for MACE prevention — semaglutide vs statin vs SGLT2i comparison Page 5

NNT for MACE prevention — semaglutide vs statin vs SGLT2i comparison

BiostatsBrad Tue, May 19, 2026 at 12:55 AM 26 replies 690 viewsPage 5 of 6
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
May 24, 2026 at 12:51 AM#21
Dr.AddMedPHL said:
Practical: whatever you change, write down the date and the reason.

This answered a question I did not know how to ask. Taking it to my next appointment.

16 16NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 13 others
Reply Quote Save Share Report
NurseAsh_DET
Member
356
1,567
Sep 2024
Detroit, MI
May 25, 2026 at 3:01 PM#22

Adding the clinical framing, because it changes how the question reads. Worth answering the question that was asked rather than the one behind it. The narrow version usually has an answer; the broad version usually does not, and answering the broad one is how a thread stops being useful.

Last edited: May 25, 2026 at 9:01 PM
15 15ricardo_MIA, BrianDallas92, labquiet_amy and 12 others
Reply Quote Save Share Report
kevin_tulsa
Member
489
2,123
Jun 2024
Tulsa, OK
May 27, 2026 at 5:09 AM#23
NurseAsh_DET said:
Worth answering the question that was asked rather than the one behind it.

This matches mine closely enough to be worth saying so out loud. Nothing to add that would improve it.

Last edited: May 27, 2026 at 7:09 AM
14 14greg_boulder, quinn_sf, NurseLeah_Nash and 11 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
May 28, 2026 at 7:17 PM#24
NurseAsh_DET said:
Worth answering the question that was asked rather than the one behind it.

Adding the part of the answer the thread has not reached. SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction in major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity, without diabetes. The effect appeared earlier than the weight-loss curve can comfortably explain, which is the basis for arguing that some of the benefit is direct — anti-inflammatory and vascular — rather than purely a consequence of weight.

13 13PeptideChemSF, A1cHero_PHX, Dr.RenalNash and 10 others
Reply Quote Save Share Report
jason_paloalto
Member
212
890
Nov 2024
Palo Alto, CA
May 30, 2026 at 9:24 AM#25

One concrete data point for the thread. One habit that pays for itself: post the method alongside the number. A figure without its method cannot be checked, and an unchecked figure is how this community accumulates folklore.

Worth separating that from cardiovascular outcomes, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Ask again with the specifics and you will get a better answer than this one.

12 12Dr.EndoEP, GraceAZ_72, carl_compliance and 9 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register